access barriers

The Community Clinical Oncology Research Network will leverage Labcorp's comprehensive genomic profiling test to build out a registry of diverse patient data. 

The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.

As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.